Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/138981
Full metadata record
DC FieldValueLanguage
dc.creatorParreira, P
dc.creatorMonteiro, C
dc.creatorGraça, V
dc.creatorGomes, J
dc.creatorMaia, S
dc.creatorGomes, P
dc.creatorGonçalves, IC
dc.creatorMartins, MCL
dc.date.accessioned2022-01-10T09:58:49Z-
dc.date.available2022-01-10T09:58:49Z-
dc.date.issued2019
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/10216/138981-
dc.description.abstractAs we approach the end of the antibiotic era, newer therapeutic options, such as antimicrobial peptides (AMPs), are in urgent demand. AMP surface grafting onto biomaterials has been described as a good strategy to overcome problems associated with their in vivo stability. Helicobacter pylori is among the bacteria that pose greatest threat to human health, being MSI-78A one of the few bactericidal AMPs against this bacterium. Here, we report that MSI-78A grafted onto model surfaces (Self-Assembled Monolayers –SAMs), in a concentration of 30.3 ± 1.2 ng/cm2 determined by quartz crystal microbalance with dissipation (QCM-D), was able to kill, by contact, 98% of planktonic H. pylori in only 2 h. This fact was not verified against the control bacteria (Staphylococcus epidermidis), although the minimal inhibitory concentration (MIC) of MSI-78A in solution is much lower for S. epidermidis (2 µg/mL) than for H. pylori (64 µg/mL). Our results also demonstrated that, in opposite to other bacteria, H. pylori cells were attracted to ethylene glycol terminated (antiadhesive) surfaces, which can explain the high bactericidal potential of grafted MSI-78A. This proof of concept study establishes the foundations for development of MSI-78A grafted nanoparticles for gastric infection management within a targeted nanomedicine concept.
dc.description.sponsorshipThis article is a result of the project NORTE-01-0145-FEDER-00012, (NORTE 2020) and FCT/MCTES-through the UID/BIM/04293/2019, PTDC/CTM-BIO/4043/2014, UID/QUI/50006/2013 (LAQV-REQUIMTE) projects. Claudia Monteiro acknowledges FCT for the SFRH/BPD/79439/2011 grant.
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147218/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBPD%2F79439%2F2011/PT
dc.relation.ispartofScientific Reports, vol.9(1):18212
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.meshAntimicrobial Cationic Peptides / administration & dosage
dc.subject.meshBiocompatible Materials / chemistry
dc.subject.meshBioengineering
dc.subject.meshDrug Delivery Systems / methods
dc.subject.meshHelicobacter Infections / drug therapy
dc.subject.meshHelicobacter Infections / microbiology
dc.subject.meshHelicobacter pylori / drug effects
dc.subject.meshHumans
dc.subject.meshMicrobial Sensitivity Tests
dc.subject.meshNanoparticles / chemistry
dc.subject.meshProof of Concept Study
dc.subject.meshQuartz Crystal Microbalance Techniques
dc.subject.meshStaphylococcus aureus / drug effects
dc.subject.meshStomach Diseases / drug therapy
dc.subject.meshStomach Diseases / microbiology
dc.titleSurface Grafted MSI-78A Antimicrobial Peptide has High Potential for Gastric Infection Management
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.1038/s41598-019-53918-4
dc.relation.publisherversionhttps://www.nature.com/articles/s41598-019-53918-4
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.1038-s41598-019-53918-4.pdf2.37 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons